Vagus nerve stimulation (VNS) is an established tool in the psychiatric armamentarium for patients with therapy-resistant depression (TRD) with response rates of approximately 60%. So far, VNS is titrated slowly during ambulatory in-office visits. Thus, antidepressive effects can be expected after approximately six months.
Introduction
Vagus nerve stimulation is an established tool in the psychiatric armamentarium for patients with therapy-resistant depression (TRD) [1] [2] [3] [4] . TRD is defined as the failure of two successive trials of antidepressant treatment administered at an appropriate dose and for sufficient duration [5, 6] . Using VNS, approximately 60% of patients with TRD show reduction in their depressive symptoms [1, 2] . Long-term follow-ups indicate fewer suicide attempts, lower levels of suicidal ideations and thoughts, and fewer hospitalizations in patients treated with VNS in addition to pharmacotherapy compared to patients with the same level of depression symptom severity who were only treated with pharmacotherapy [2, 4, 7] . According to clinical expertise, VNS stimulation begins two weeks after implantation [8] . The treating physician uses a handheld computer and telemetric wand to modulate the stimulation parameters. Frequent ambulatory in-office visits are needed to set-up the parameters of the stimulator [4] .
Here, we report our positive findings of a rapid dose titration regime starting immediately after implantation of VNS.
Material and methods
In this study, data of six patients who received VNS were analyzed retrospectively (Table 1) pharmacotherapy, were evaluated consequently with regard to common clinical side effects of VNS, blood pressures (mmHg) and heart rates (bpm). Depressive symptoms were assessed via Montgomery-Asberg Depression Rating Scale (MADRS) [9] . The MADRS was administered one week before implantation of the vagus nerve stimulator and three months after implantation.
We tested for normal distribution using the Shapiro-Wilk test. Correlation between different time points (before stimulation and during the titration period) and heart rates as well as systolic and diastolic blood pressures was assessed via Spearman rank correlation testing. Differences in MADRS scores were assessed by Wilcoxon-test for paired samples.
Results
The first titration period was done in an in-patient setting. All patients received first stimulation between one and four days after surgery, which is a novel titration regime first presented herein. We elevated the output current using 0.25 mA titration steps. We increased the output current between one and four days after last titration. All patients received 1.0 mA output current after eight to 14 days post-surgery. In all patients heart rates and blood pressures did not correlate with the different time points (p > 0.05). Hoarseness was observed in all patients, coughing and pain was reported by only one patient each. All side effects were mild and temporary. There were no side effects on the central nervous system. MADRS scores were significantly lower three months after surgery (mean ± SD: 24 ± 8) than one week before VNS implantation (42 ± 4; p = 0.028) (Fig. 1 ).
Discussion
Our preliminary data support the conclusion that a rapid dosing regime for VNS is safe and does not lead to an increased number of harmful side effects. Usually, dosing titration starts two weeks after surgery [4] and stimulation is increased by 0.25 mA per visit during psychiatric in-office visits. Consequently, frequent visits are needed to reach the therapeutic range between 1.0 and 2.0 mA [3, 4] . Thus, treatment results can be expected after approximately four to six months of VNS therapy [3, 4] . Aaronson et al. showed that the total charge of the VNS delivered per day correlates with decreasing depressive symptoms [10] . Thus, to reach optimal effectiveness of VNS a preferably high output current would be desirable. Moreover, higher electrical dose parameters are associated with response durability [10] . Additionally, the stimulation amplitude must be optimized with respect to tolerability [3, 4] . None of our patients had temporary side effects on the central nervous system, e.g. dizziness, fatigue, psychomotoric slowdown or cognitive impairment [11] .
In the light of that findings the usual slow and careful increase of the output current of the VNS does not seem to be necessary.
All our patients were programmed at minimally 1.0 mA output current within 14 days after implantation of the VNS, i.e. at the minimum therapeutic output current where antidepressive action can be expected. Although we only assessed six patients with severe major depressive disorder, depression severity in our sample measured by MADRS already significantly improved after three months. In our study the antidepressive effects were reached quicker than previously described [2] . Thus, severely depressed patients might reach remission earlier and have a sustained antidepressive effect with the newly described VNS dosing regime herein. This could be a valuable finding under the light of closing the gap in antidepressive treatment latency of VNS.
Moreover, the side effects that occurred in our patient cohort were well known, only low in intensity and temporary. As the patients were on-ward physicians were able to immediately react to patient side effects. However, because of the only low and transient unwanted secondary effects it seems possible to perform a dynamic dosing regime also in an ambulatory setting.
To conclude, for the first time we presented a dynamic novel titration regime for vagus nerve stimulation in severe depressive patients. Using the rapid dosing regime the full antidepressive VNS effect for patients could be reached earlier than using the slower titration regime during ambulatory in-office visits. We only observed the same local side effects which are known from the slow titration regime.
However, we are aware of the small sample size of only six patients. Thus, our preliminary results have to be controlled in larger clinical samples.
Our presented dynamic dosing regime might be able to significantly shorten the ''clinical effect gap" due to the neurobiological and titration-related latency [3, 4] . Fig. 1 . Montgomery-Asberg Depression Rating Scale (MADRS) one week before implantation and three months after surgery.
